Kingsman Wealth Management Reduces Stake in Eli Lilly by 62%

Kingsman Wealth Management Inc. has significantly reduced its holdings in Eli Lilly and Company (NYSE: LLY) by 62.1% during the third quarter of 2023. According to HoldingsChannel.com, the institutional investor sold 879 shares, bringing its total to 537 shares, valued at approximately $410,000 at the end of the reporting period.

Several other institutional investors and hedge funds have also adjusted their positions in Eli Lilly. Notably, Investment Partners Asset Management Inc. increased its holdings by 109.4%, acquiring an additional 420 shares during the last quarter, bringing its total to 804 shares worth $613,000. Ascent Group LLC and Baron Wealth Management LLC also made notable increases, raising their stakes by 3.3% and 4.0%, respectively.

Market Activity and Analyst Ratings

Eli Lilly’s stock has seen a mixed response from analysts. On December 19, 2023, Sanford C. Bernstein reaffirmed an “outperform” rating. Morgan Stanley raised its target price from $1,171.00 to $1,290.00 and maintained an “overweight” rating. Other firms, including JPMorgan Chase & Co. and Leerink Partners, have also issued optimistic projections for the pharmaceutical giant.

Currently, four research analysts have rated Eli Lilly’s stock with a “Strong Buy,” while seventeen have given a “Buy” rating and five assigned it a “Hold” rating. The average price target stands at $1,155.36, indicating a generally positive outlook among market analysts.

As of the latest trading session, Eli Lilly and Company opened at $1,075.00, reflecting a 0.4% decrease. The company maintains a market capitalization of $1.02 trillion and has reported a price-to-earnings ratio of 52.59.

Financial Performance and Future Guidance

Eli Lilly announced impressive financial results on October 30, 2023, reporting earnings per share (EPS) of $7.02, exceeding the consensus estimate of $6.42 by $0.60. The company generated revenue of $17.60 billion for the quarter, significantly higher than the anticipated $16.09 billion. This reflects a remarkable 53.9% increase compared to the previous year.

The company has set its guidance for the fiscal year 2025 at an EPS range of 23.000-23.700. Analysts project an average EPS of 23.48 for the current year.

In addition to its robust financial performance, Eli Lilly has also announced a quarterly dividend of $1.73, scheduled for payment on March 10, 2024. Shareholders of record as of February 13, 2024 will receive this dividend, which represents an increase from the previous quarterly dividend of $1.50. This increase marks an annualized dividend of $6.92, yielding approximately 0.6%.

Eli Lilly and Company, founded in 1876 and headquartered in Indianapolis, Indiana, continues to be a significant player in the global pharmaceutical market, with operations spanning North America, Europe, Asia, and other regions. The company’s commitment to research and development remains a cornerstone of its strategy to deliver advanced therapies to patients worldwide.